Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans. …
Immutep and Monash announce first publication detailing how human LAG-3 Binds to MHC Class II
December 16, 2024 Australian Biotech
Latest Video
New Stories
-
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 - - Australian Biotech -
Arrotex Pharmaceuticals appointed exclusive partner for Juniper Biologics
May 29, 2025 - - Latest News -
TGA approves new therapy for children with growth hormone deficiency
May 29, 2025 - - Latest News -
AbbVie Australia appoints Dr Carly Levetan associate medical director
May 29, 2025 - - Latest News -
For patients, it's about understanding their experience and accessing the touchpoints
May 29, 2025 - - Latest News -
Priceline Pharmacy launches annual event with national menopause project
May 28, 2025 - - Latest News -
Anne Ruston welcomes her reappointment to health and the addition of NDIS
May 28, 2025 - - Latest News